Odyssey Therapeutics' IPO

Listed May 8, 2026 at $18 on Nasdaq as ODTX.

Offer price
$18
Shares
15,500,000
Ticker
ODTX

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed May 8, 2026.

What does Odyssey Therapeutics do?

“Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases.”
From its final prospectus (424B4), filed May 8, 2026
Odyssey Therapeutics' facts, each with its source
FactOdyssey
Therapeutics
IncorporatedDelaware, 2021From its final prospectus (424B4) of May 8, 2026
HeadquartersBoston, MassachusettsFrom its final prospectus (424B4) of May 8, 2026
Employees100 full-time, as of March 31, 2026From its final prospectus (424B4) of May 8, 2026
Websiteodysseytx.comFrom its final prospectus (424B4) of May 8, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Odyssey Therapeutics' facts, each with its source
FactOdyssey
Therapeutics
Shares offered15,500,000From the final prospectus (424B4) filed May 8, 2026
Offer price$18 a shareFrom the final prospectus (424B4) filed May 8, 2026
Raised at that price$279 millionFrom the final prospectus (424B4) filed May 8, 2026
Underwriters' discount$19.5 millionFrom the final prospectus (424B4) filed May 8, 2026
Underwriters' option2,325,000 more sharesFrom the final prospectus (424B4) filed May 8, 2026
UnderwritersJ.P. Morgan, TD Cowen, Cantor, Wedbush, and OppenheimerFrom the final prospectus (424B4) filed May 8, 2026, as its cover names them
ExchangeNasdaq Capital Market, as ODTXFrom the final prospectus (424B4) filed May 8, 2026

What the filing says about its money

Odyssey Therapeutics' facts, each with its source
FactOdyssey
Therapeutics
Collaboration revenue$3 million, year to December 31, 2025From its final prospectus (424B4) of May 8, 2026, its summary financial data
Net loss$149 million, year to December 31, 2025From its final prospectus (424B4) of May 8, 2026, its summary financial data
Last preferred stockSeries D preferredFrom its final prospectus (424B4) of May 8, 2026

What risks does Odyssey Therapeutics name first?

  1. “We are a clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses, have no products approved for commercial sale, have never generated revenue from product sales and may never be profitable.”
  2. “Even if this offering and the concurrent private placement are successful, we will require substantial additional capital to finance our operations.”
  3. “Our business depends entirely on the success of our product candidates and development programs, including OD-001 and OD-002, and we cannot guarantee that any or all of our current or future product candidates will successfully complete clinical development…”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Odyssey Therapeutics' IPO

Odyssey Therapeutics' IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARJan 17, 2025
Exchange registration filedexchange registration (Form 8-A), SEC EDGARMay 5, 2026
Declared effective by the SECSEC notice of effectiveness, SEC EDGARMay 7, 2026
Pricedfinal prospectus (424B4), filed May 8, SEC EDGARMay 7, 2026
First tradeMassive's IPO calendarMay 8, 2026
Lock-up endsfinal prospectus, SEC EDGAR: “”Nov 3, 2026

How did its first days trade?

From its daily bars, each close against its $18 offer price.

Odyssey Therapeutics' first sessions
DayOpenCloseFrom the
offer
May 8$20$16.42-8.8%
May 11$16.56$17.45-3.1%
May 12$17.61$17.90-0.6%
May 13$18.06$17.94-0.3%
May 14$17.92$17.32-3.8%

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Odyssey Therapeutics IPO questions

When is Odyssey Therapeutics' IPO?

Listed May 8, 2026 at $18 on Nasdaq as ODTX.

What is Odyssey Therapeutics' IPO price?

Odyssey Therapeutics' IPO priced at $18 a share, per its final prospectus of May 8, 2026.

How many shares is Odyssey Therapeutics selling?

15,500,000 shares, and the underwriters may buy 2,325,000 more, per its final prospectus (424B4).

Who are the underwriters?

J.P. Morgan, TD Cowen, Cantor, Wedbush, and Oppenheimer, as the prospectus's cover names them.

When does the lock-up end?

Odyssey Therapeutics' IPO lock-⁠up ends Nov 3, 2026. Its final prospectus says: “.”

Does Breakaway rate Odyssey Therapeutics?

Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.

Can Breakaway say where Odyssey Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

  • Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
  • The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
  • The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
  • The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
  • Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and May 2026's listings.

Sources: Odyssey Therapeutics, Inc.'s final prospectus (424B4) of May 8, 2026; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.